dalteparin has been researched along with Arterial Occlusive Diseases in 28 studies
Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
Arterial Occlusive Diseases: Pathological processes which result in the partial or complete obstruction of ARTERIES. They are characterized by greatly reduced or absence of blood flow through these vessels. They are also known as arterial insufficiency.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The Fraxiparin in Stroke Study for the treatment of ischemic stroke (FISS-tris) study showed no superiority of low-molecular-weight heparin (LMWH) over aspirin for the primary end point (Barthel Index) in acute ischemic stroke due to large artery occlusive disease." | 9.16 | Low-molecular-weight heparin versus aspirin for acute ischemic stroke with large artery occlusive disease: subgroup analyses from the Fraxiparin in Stroke Study for the treatment of ischemic stroke (FISS-tris) study. ( Chen, C; Chen, XY; Han, JH; Leung, TW; Mok, V; Soo, Y; Wang, QS; Wong, KS, 2012) |
| " We present a unique case of ET causing extensive arterial thromboembolism, despite being on adequate antithrombotic agents including warfarin and aspirin." | 7.85 | Medical Management of Extensive Arterial Thromboembolism in a Patient with Essential Thrombocythemia and Warfarin Failure. ( Ahmed, AK; Skeik, N; Youssef, A, 2017) |
| "Warfarin-induced skin necrosis is a rare complication associated with the use of oral anticoagulants." | 7.72 | A case of warfarin skin necrosis despite enoxaparin anticoagulation in a patient with protein S deficiency. ( Alexander, JB; Ierardi, R; Tai, CY, 2004) |
| " Our case report suggests that antithrombotic treatment by targeting of the activated platelets with a potent platelet inhibitor during the acute phase of type II HIT syndrome followed by long-term administration of oral anticoagulation may be an additional, safe and effective therapeutic alternative that merits to be systematically studied." | 5.33 | Recurrent arterial thromboses in a woman with heparin induced thrombocytopenia, successfully managed with iloprost followed by clopidogrel. An alternative therapeutic option for heparin induced thrombocytopenia type II syndrome. ( Alexandridou, S; Betsis, D; Blouhos, K; Megalopoulos, A; Tsachalis, T; Tsalis, K; Vasiliadis, K, 2006) |
| "The Fraxiparin in Stroke Study for the treatment of ischemic stroke (FISS-tris) study showed no superiority of low-molecular-weight heparin (LMWH) over aspirin for the primary end point (Barthel Index) in acute ischemic stroke due to large artery occlusive disease." | 5.16 | Low-molecular-weight heparin versus aspirin for acute ischemic stroke with large artery occlusive disease: subgroup analyses from the Fraxiparin in Stroke Study for the treatment of ischemic stroke (FISS-tris) study. ( Chen, C; Chen, XY; Han, JH; Leung, TW; Mok, V; Soo, Y; Wang, QS; Wong, KS, 2012) |
| "After successful PTA, 275 patients with symptomatic peripheral arterial disease (claudication or critical limb ischemia) and femoropopliteal obstructions were randomized to receive either 2500 IU of dalteparin subcutaneously for 3 months plus 100 mg of aspirin daily (n = 137), or 100 mg aspirin daily alone (n = 138)." | 5.12 | Low-molecular-weight heparin for prevention of restenosis after femoropopliteal percutaneous transluminal angioplasty: a randomized controlled trial. ( Amann-Vesti, BR; Banyai, M; Koppensteiner, R; Meier, T; Pfammatter, T; Rousson, V; Spring, S; van der Loo, B, 2006) |
| "We report a case of ophthalmic artery occlusion (OAO) in a young patient with COVID-19 infection that was on therapeutic anticoagulation with apixaban for deep venous thrombosis (DVT)." | 3.96 | Acute ophthalmic artery occlusion in a COVID-19 patient on apixaban. ( Biousse, V; Bose, S; Dumitrascu, OM; Lyden, PD; Volod, O; Wang, Y, 2020) |
| " We present a unique case of ET causing extensive arterial thromboembolism, despite being on adequate antithrombotic agents including warfarin and aspirin." | 3.85 | Medical Management of Extensive Arterial Thromboembolism in a Patient with Essential Thrombocythemia and Warfarin Failure. ( Ahmed, AK; Skeik, N; Youssef, A, 2017) |
| "Warfarin-induced skin necrosis is a rare complication associated with the use of oral anticoagulants." | 3.72 | A case of warfarin skin necrosis despite enoxaparin anticoagulation in a patient with protein S deficiency. ( Alexander, JB; Ierardi, R; Tai, CY, 2004) |
| " The general use and correct dosage of low-molecular-weight heparin, however, are still under debate." | 2.70 | Low-molecular-weight heparin in arterial reconstructive surgery: a double-blind, randomized dose-finding trial. ( Eckmann, C; Kujath, P; Misselwitz, F, 2002) |
| "BACKGROUND Coronavirus disease 2019 (COVID-19) has a tremendous impact on the respiratory tract." | 1.72 | A Patient-Tailored Approach to Management of Acute Limb Ischemia in Patients with COVID-19: A Case Series. ( AlGhofili, H; Alhumaid, A; Aljabri, B; Altoijry, A; Iqbal, K, 2022) |
| " In the patients of both groups the product dabigatran etexilate in the standard dosage (220 mg/day) was used for specific prevention." | 1.43 | [Substantiation of the system of thrombus formation prevention in treatment of patients with hip joint pathology against the background of arterial insufficiency of the lower extremities]. ( Akhtyamov, IF; Shigaev, ES; Ziatdinov, BG, 2016) |
| " Protocols vary from center to center, but there is still no consensus regarding the proper dosage or treatment duration." | 1.42 | The Use of Low-Dose Recombinant Tissue Plasminogen Activator to Treat a Preterm Infant with an Intrauterine Spontaneous Arterial Thromboembolism. ( Caner, İ; Demirelli, Y; Kara, M; Tekgündüz, KŞ, 2015) |
| "Acute pulmonary embolism is an important emergency disease which frequently results in life-threatening complication." | 1.39 | Effectiveness of low-dose prolonged infusion of tissue plasminogen activator in a nonagenarian patient with acute pulmonary embolism and main pulmonary artery thrombus. ( Acar, RD; Karakoyun, S; Ozkan, M; Yildiz, M, 2013) |
| "Dabigatran was stopped and dalteparin 5000 International Units/bid and 40 μg alprostadil infusions were started." | 1.38 | Fatal basilar artery occlusion under dabigatran occurring 13 days after femoral embolectomy. ( Finsterer, J; Reiter, M; Schäffl-Doweik, L; Stöllberger, C, 2012) |
| " Our case report suggests that antithrombotic treatment by targeting of the activated platelets with a potent platelet inhibitor during the acute phase of type II HIT syndrome followed by long-term administration of oral anticoagulation may be an additional, safe and effective therapeutic alternative that merits to be systematically studied." | 1.33 | Recurrent arterial thromboses in a woman with heparin induced thrombocytopenia, successfully managed with iloprost followed by clopidogrel. An alternative therapeutic option for heparin induced thrombocytopenia type II syndrome. ( Alexandridou, S; Betsis, D; Blouhos, K; Megalopoulos, A; Tsachalis, T; Tsalis, K; Vasiliadis, K, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (3.57) | 18.2507 |
| 2000's | 12 (42.86) | 29.6817 |
| 2010's | 13 (46.43) | 24.3611 |
| 2020's | 2 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Bang, OY | 1 |
| Kim, JS | 1 |
| Wang, QS | 1 |
| Chen, C | 2 |
| Chen, XY | 1 |
| Han, JH | 1 |
| Soo, Y | 1 |
| Leung, TW | 1 |
| Mok, V | 1 |
| Wong, KS | 2 |
| Mazzone, A | 1 |
| Giani, L | 1 |
| Faggioli, P | 1 |
| Pichini, S | 1 |
| Pacifici, R | 1 |
| Ng, PW | 1 |
| Tsoi, TH | 1 |
| Li, HL | 1 |
| Fong, WC | 1 |
| Yeung, J | 1 |
| Wong, CK | 1 |
| Yip, KK | 1 |
| Gao, H | 1 |
| Wong, HB | 1 |
| Schweizer, J | 1 |
| Müller, A | 1 |
| Forkmann, L | 1 |
| Hellner, G | 1 |
| Kirch, W | 1 |
| Camporese, G | 1 |
| Bernardi, E | 1 |
| Noventa, F | 1 |
| Alhumaid, A | 1 |
| Altoijry, A | 1 |
| Aljabri, B | 1 |
| Iqbal, K | 1 |
| AlGhofili, H | 1 |
| Dumitrascu, OM | 1 |
| Volod, O | 1 |
| Bose, S | 1 |
| Wang, Y | 1 |
| Biousse, V | 1 |
| Lyden, PD | 1 |
| Demirelli, Y | 1 |
| Tekgündüz, KŞ | 1 |
| Caner, İ | 1 |
| Kara, M | 1 |
| Beato, J | 1 |
| Fígueira, L | 1 |
| Penas, S | 1 |
| Santos-Silva, R | 1 |
| Falcão, M | 1 |
| Carneiro, Â | 1 |
| Reis, FF | 1 |
| Akhtyamov, IF | 1 |
| Ziatdinov, BG | 1 |
| Shigaev, ES | 1 |
| Ahmed, AK | 1 |
| Youssef, A | 1 |
| Skeik, N | 1 |
| Feray, H | 1 |
| Izgi, C | 1 |
| Cetiner, D | 1 |
| Men, EE | 1 |
| Saltan, Y | 1 |
| Baltay, A | 1 |
| Kahraman, R | 1 |
| Raynaud, A | 1 |
| Novelli, L | 1 |
| Rovani, X | 1 |
| Carreres, T | 1 |
| Bourquelot, P | 1 |
| Hermelin, A | 1 |
| Angel, C | 1 |
| Beyssen, B | 1 |
| Duschek, N | 1 |
| Vafaie, M | 1 |
| Skrinjar, E | 1 |
| Hirsch, K | 1 |
| Waldhör, T | 1 |
| Hübl, W | 1 |
| Bergmayr, W | 1 |
| Knoebl, P | 1 |
| Assadian, A | 1 |
| Stöllberger, C | 1 |
| Reiter, M | 1 |
| Schäffl-Doweik, L | 1 |
| Finsterer, J | 1 |
| Yildiz, M | 1 |
| Karakoyun, S | 1 |
| Acar, RD | 1 |
| Ozkan, M | 1 |
| Tai, CY | 1 |
| Ierardi, R | 1 |
| Alexander, JB | 1 |
| Hans, GA | 1 |
| Senard, M | 1 |
| Ledoux, D | 1 |
| Grayet, B | 1 |
| Scholtes, F | 1 |
| Creemers, E | 1 |
| Lamy, ML | 1 |
| Kujath, P | 1 |
| Eckmann, C | 1 |
| Misselwitz, F | 1 |
| Göttman, D | 1 |
| Strecker, EP | 1 |
| Boos, I | 1 |
| Vetter, S | 1 |
| Skeppholm, M | 1 |
| Kallner, A | 1 |
| Kalani, M | 2 |
| Jörneskog, G | 2 |
| Blombäck, M | 2 |
| Wallén, HN | 1 |
| Pokrovskiĭ, AV | 1 |
| Gontarenko, VN | 1 |
| Titova, MI | 1 |
| Apelqvist, J | 1 |
| Brismar, K | 1 |
| Eliasson, B | 1 |
| Eriksson, JW | 1 |
| Fagrell, B | 1 |
| Hamsten, A | 1 |
| Torffvit, O | 1 |
| Kovacs, MJ | 1 |
| Kearon, C | 1 |
| Rodger, M | 1 |
| Anderson, DR | 1 |
| Turpie, AG | 1 |
| Bates, SM | 1 |
| Desjardins, L | 1 |
| Douketis, J | 1 |
| Kahn, SR | 1 |
| Solymoss, S | 1 |
| Wells, PS | 1 |
| Koppensteiner, R | 1 |
| Spring, S | 1 |
| Amann-Vesti, BR | 1 |
| Meier, T | 1 |
| Pfammatter, T | 1 |
| Rousson, V | 1 |
| Banyai, M | 1 |
| van der Loo, B | 1 |
| Telen, MJ | 1 |
| Batchvarova, M | 1 |
| Shan, S | 1 |
| Bovee-Geurts, PH | 1 |
| Zennadi, R | 1 |
| Leitgeb, A | 1 |
| Brock, R | 1 |
| Lindgren, M | 1 |
| Megalopoulos, A | 1 |
| Vasiliadis, K | 1 |
| Tsachalis, T | 1 |
| Tsalis, K | 1 |
| Blouhos, K | 1 |
| Alexandridou, S | 1 |
| Betsis, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Double Blind Randomized Control Trial of Post-Operative Low Molecular Weight Heparin Bridging Therapy Versus Placebo Bridging Therapy for Patients Who Are at High Risk for Arterial Thromboembolism (PERIOP 2)[NCT00432796] | Phase 3 | 1,473 participants (Actual) | Interventional | 2006-12-31 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for dalteparin and Arterial Occlusive Diseases
| Article | Year |
|---|---|
Update on the clinical use of the low-molecular-weight heparin, parnaparin.
Topics: Acute Coronary Syndrome; Anticoagulants; Arterial Occlusive Diseases; Cardiovascular Diseases; Drug | 2009 |
[Administration of dalteparin in reconstructive vascular surgery].
Topics: Anticoagulants; Arterial Occlusive Diseases; Arteries; Blood Coagulation; Blood Coagulation Factors; | 2011 |
9 trials available for dalteparin and Arterial Occlusive Diseases
| Article | Year |
|---|---|
Low-molecular-weight heparin versus aspirin for acute ischemic stroke with large artery occlusive disease: subgroup analyses from the Fraxiparin in Stroke Study for the treatment of ischemic stroke (FISS-tris) study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arterial Occlusive Diseases; As | 2012 |
Low-molecular-weight heparin compared with aspirin for the treatment of acute ischaemic stroke in Asian patients with large artery occlusive disease: a randomised study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Arterial Occlusive Diseases; A | 2007 |
Potential use of a low-molecular-weight heparin to prevent restenosis in patients with extensive wall damage following peripheral angioplasty.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angioplasty, Balloon; Anticoagulants; Arterial Occlusive | 2001 |
Comparison of enoxaparin and unfractionated heparin in endovascular interventions for the treatment of peripheral arterial occlusive disease: a randomized controlled trial.
Topics: Aged; Arterial Occlusive Diseases; Aspirin; Drug Therapy, Combination; Endothelium, Vascular; Enoxap | 2011 |
Low-molecular-weight heparin in arterial reconstructive surgery: a double-blind, randomized dose-finding trial.
Topics: Aged; Anticoagulants; Arterial Occlusive Diseases; Blood Vessel Prosthesis Implantation; Dose-Respon | 2002 |
[Dose-dependent decrease of the rate of restenosis of stents in peripheral vessels with reviparin].
Topics: Aged; Angiography, Digital Subtraction; Anticoagulants; Arterial Occlusive Diseases; Dose-Response R | 1999 |
Effect of dalteparin on healing of chronic foot ulcers in diabetic patients with peripheral arterial occlusive disease: a prospective, randomized, double-blind, placebo-controlled study.
Topics: Age of Onset; Aged; Aged, 80 and over; Arterial Occlusive Diseases; Body Mass Index; Dalteparin; Dia | 2003 |
Single-arm study of bridging therapy with low-molecular-weight heparin for patients at risk of arterial embolism who require temporary interruption of warfarin.
Topics: Anticoagulants; Arterial Occlusive Diseases; Aspirin; Atrial Fibrillation; Blood Loss, Surgical; Coh | 2004 |
Low-molecular-weight heparin for prevention of restenosis after femoropopliteal percutaneous transluminal angioplasty: a randomized controlled trial.
Topics: Aged; Angioplasty, Balloon; Arterial Occlusive Diseases; Aspirin; Dalteparin; Drug Therapy, Combinat | 2006 |
17 other studies available for dalteparin and Arterial Occlusive Diseases
| Article | Year |
|---|---|
Low-molecular-weight heparin in atherosclerotic stroke: a surprising resurrection of anticoagulants?
Topics: Antifibrinolytic Agents; Arterial Occlusive Diseases; Aspirin; Brain Ischemia; Female; Humans; Intra | 2012 |
Cocaine-related peripheral vascular occlusive disease treated with iloprost in addition to anticoagulants and antibiotics.
Topics: Acute Disease; Adult; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Anticoag | 2007 |
A Patient-Tailored Approach to Management of Acute Limb Ischemia in Patients with COVID-19: A Case Series.
Topics: Adult; Aged; Arterial Occlusive Diseases; COVID-19; Enoxaparin; Female; Humans; Ischemia; Male; Midd | 2022 |
Acute ophthalmic artery occlusion in a COVID-19 patient on apixaban.
Topics: Arterial Occlusive Diseases; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatm | 2020 |
The Use of Low-Dose Recombinant Tissue Plasminogen Activator to Treat a Preterm Infant with an Intrauterine Spontaneous Arterial Thromboembolism.
Topics: Arterial Occlusive Diseases; Brachial Artery; Dose-Response Relationship, Drug; Drug Therapy, Combin | 2015 |
Presumed bilateral cilioretinal artery occlusion related to relapsing white dot syndrome.
Topics: Arterial Occlusive Diseases; Aspirin; Ciliary Arteries; Coloring Agents; Drug Therapy, Combination; | 2016 |
[Substantiation of the system of thrombus formation prevention in treatment of patients with hip joint pathology against the background of arterial insufficiency of the lower extremities].
Topics: Aged; Anticoagulants; Arterial Occlusive Diseases; Arthroplasty, Replacement, Hip; Blood Coagulation | 2016 |
Medical Management of Extensive Arterial Thromboembolism in a Patient with Essential Thrombocythemia and Warfarin Failure.
Topics: Anticoagulants; Arterial Occlusive Diseases; Blood Coagulation; Blood Coagulation Tests; Computed To | 2017 |
Effectiveness of enoxaparin for prevention of radial artery occlusion after transradial cardiac catheterization.
Topics: Arterial Occlusive Diseases; Cardiac Catheterization; Enoxaparin; Female; Follow-Up Studies; Humans; | 2010 |
Radiocephalic fistula complicated by distal ischemia: treatment by ulnar artery dilatation.
Topics: Aged; Angioplasty, Balloon; Arterial Occlusive Diseases; Catheters, Indwelling; Clopidogrel; Diabete | 2010 |
Fatal basilar artery occlusion under dabigatran occurring 13 days after femoral embolectomy.
Topics: Aged; Anticoagulants; Antithrombins; Arterial Occlusive Diseases; Atrial Fibrillation; Benzimidazole | 2012 |
Effectiveness of low-dose prolonged infusion of tissue plasminogen activator in a nonagenarian patient with acute pulmonary embolism and main pulmonary artery thrombus.
Topics: Acute Disease; Aged, 80 and over; Anticoagulants; Arterial Occlusive Diseases; Drug Substitution; Em | 2013 |
A case of warfarin skin necrosis despite enoxaparin anticoagulation in a patient with protein S deficiency.
Topics: Anticoagulants; Arterial Occlusive Diseases; Enoxaparin; Female; Fibrinolytic Agents; Heparin, Low-M | 2004 |
Cerebral subarachnoid blood migration consecutive to a lumbar haematoma after spinal anaesthesia.
Topics: Aged; Anesthesia, Spinal; Anesthetics, Intravenous; Anesthetics, Local; Angioplasty, Balloon; Arteri | 2008 |
ADAMTS13 and von Willebrand factor concentrations in patients with diabetes mellitus.
Topics: ADAM Proteins; ADAMTS13 Protein; Adult; Aged; Aged, 80 and over; Arterial Occlusive Diseases; Case-C | 2009 |
Sevuparin binds to multiple adhesive ligands and reduces sickle red blood cell-induced vaso-occlusion.
Topics: Anemia, Sickle Cell; Animals; Arterial Occlusive Diseases; Cell Adhesion; Cells, Cultured; Endotheli | 2016 |
Recurrent arterial thromboses in a woman with heparin induced thrombocytopenia, successfully managed with iloprost followed by clopidogrel. An alternative therapeutic option for heparin induced thrombocytopenia type II syndrome.
Topics: Aged; Arterial Occlusive Diseases; Clopidogrel; Drug Therapy, Combination; Female; Fibrinolytic Agen | 2006 |